Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

The Clinical Features and Pregnancy Outcomes of CTD Patients

NCT04918524 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2018-09-11
Last updated
2023-11-18

Condition(s) studied

Connective Tissue DiseasesPregnancy Related

Investigational drug(s) / intervention(s)

Prednisone →Hydroxychloroquine →Aspirin →low molecular weight heparin Enoxaparin →

Prednisone: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response

Hydroxychloroquine: 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.

Aspirin: 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.

low molecular weight heparin Enoxaparin: 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.

Study summary

Connective tissue disease (CTD) is a common group of autoimmune diseases, mainly including systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) , and so on. APS is caused by autoimmune disorders that cause recurrent miscarriage, thrombosis, and thrombocytopenia, and often secondary to connective tissue diseases such as SLE. Undifferentiated connective tissue disease (UCTD) is currently considered to be an independent disease in the classification of CTD. And women of childbearing age who suffer UCTD is more common than that in other definite CTDs. Therefore, the impact of the disease flare and the influence of medicine on pregnancy and lactation are important for these patients who may suffer high-risk of abnormal pregnance.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Women who meet the following inclusion criteria will be eligible to participate in the study: 1. Age between 20-45 years; 2. Diagnosed with APS: patients meet the Sydney classification criteria; 3. Diagnosed with UCTD: at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-doublestranded DNA (ds-DNA) antibody, antiphospholipid antibody(aPL), and non-criteria aPL (NC-aPL), with at least one symptoms or signs suggesting connective tissue disease(CTD) , while not fulfilling any classification criteria of a defined CTD. 4. Participate voluntarily in this study, willing to use medication and follow-up according to treatment plan, and sign informed consent. Exclusion Criteria: * Women who meet any of the following criteria will be excluded from the study: 1.Any known etiology of previous pregnancy loss: 1. Known paternal, maternal or embryo chromosome abnormality. 2. Maternal endocrine dysfunction: corpus luteal insufficiency; polycystic ovarian syndrome; premature ovarian failure (follicle stimulating hormone, FSH ≥20uU/L in follicular phase); 3. hyperprolactinemia; diabetes mellitus; other hypothalamic pituitary-adrenal axis abnormality 4. Maternal anatomical abnormality: uterine malformation; Asherman syndrome; cervical incompetence; uterine fibrosis more than 5 cm.Vaginal infection. 5. Any known severe cardiac, hepatic, renal, hematological or endocrinal diseases: 2\. Any active infection: Active infection including V aricella zostervirus(VZV), human immunodeficiency virus (HIV), Human papillomavirus (HPV),syphilis or tuberculosis. 3\. Allergic to prednisone, hydroxychloroquine, low-molecular-weight heparin or aspirin. 4.Disease history as follows: 1. Past history of digestive ulcers or upper gastrointestinal hemorrhage. 2. Past history of malignancy. 3. Past history of epilepsia or psychotic disorders. 5.Women have been diagnosed with Systemic lupus erythematosus 6\. Women who disagree or cannot complete pregnancy and follow-up after delivery.

Primary outcome measure(s)

  • Live birth rate — After 28 weeks of gestation
    Percentage of all patients that lead to live birth after 28 weeks of gestation

Trial sites (1)

FacilityCityRegionStatus
Qilu Hospital Jinan Shandong Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04918524 on ClinicalTrials.gov ↗ ← All trials in China